Abstract: Our results revealed OATP1B1 and OATP1B3 as high-affinity paclitaxel transporters expressed in ovarian cancer cell lines and tumor tissues, suggesting a role for these polypeptides in the disposition of paclitaxel during therapy. 
Introduction
Ovarian cancer is often diagnosed at an advanced stage because early symptoms are inconspicuous and reliable diagnostic biomarkers are not available [1] . This contributes to a poor 5-year overall survival rate of < 40% and a high death rate [2] . A combination of paclitaxel together with platinum derivatives is applied in standard chemotherapy after initial surgery on the tumor [3] . Although high response rates to this initial regimen are observed, a relapse is seen in two-thirds of patients. This is due to the rapid development of drug resistance, which is often caused by a reduced accumulation of the drug in cancer cells [4, 5] .
It is well established that overexpression of ATP-powered efflux pumps such as P-glycoprotein (P-gp) or MDR1, encoded by the ABCB1 gene, induce drug resistance to cytotoxic agents including paclitaxel [6] . Indeed, taxane resistance due to overexpression of P-glycoprotein (MDR1) has been shown in ovarian cancer [7] .
Overexpression of the multidrug resistance-related proteins MRP2 (ABCC2), MRP3 (ABCC3) and MRP7 (ABCC10) have been identified as paclitaxel-resistance factors in various cell lines and tumor tissues including HER-2-amplified breast carcinoma and non-small-cell lung cancer [8] [9] [10] . However, uptake mechanisms into tumor cells might be even more important than efflux transporters for the efficacy of anticancer drugs because they are determinants for intracellular drug concentration [11] .
One of the most important cellular drug uptake mechanisms in humans is via members of the organic anion-transporting polypeptide family (OATP) [12, 13] . Official nomenclature differentiates between genes and protein, using the terms "SLCO" and "OATP," respectively [14] . To facilitate readability and understanding of this manuscript, "OATP" is used for both genes and proteins. OATPs are expressed in a variety of tissues [15] and tumors [16, 17] , where they mediate the transport of endogenous and exogenous compounds, including drugs [12, 13, 18] . Studies have shown that uptake transporters can confer sensitivity to anticancer agents [19] [20] [21] [22] [23] , such as the OATP1B3 substrate methotrexate [19] . This may be therapeutically important because expression of OATP varies greatly among tumor cell lines [24}.
Cellular uptake of paclitaxel is known to be facilitated by OATP1B3 in Xenopus laevis oocytes [25] and by Oatp1a/1b in mice, strongly affecting plasma levels and tissue distribution of paclitaxel [28] . Furthermore, it was shown that paclitaxel is also transported by the organic anion transporter 2 (OAT2; gene: SLC22A7) [26] expressed in humans, predominantly in the liver and kidney [27] . It is unknown whether OAT2 is also expressed in human cancer cells. As OATPs exhibit overlapping substrate specificity, we hypothesized that additional OATPs may also contribute to the uptake of paclitaxel. To gain further insight into the possible role of OATP transporters in the chemoresistance of ovarian cancer, we characterized the OATP mRNA expression profiles in estrogen-responsive OVCAR-3 [29] and the estrogen-independent SK-OV-3 [30] ovarian cancer cell lines, and we investigated paclitaxel transport in X. laevis oocytes expressing all human OATPs. Our results demonstrate that paclitaxel uptake in OATP1B1 and OATP1B3 correlated with OATP1 and OATP3 mRNA expression, indicating a role for these transporters in tumor therapy. (PAN-Biotech GmbH, Aidenbach, Germany), 10% FCS and 1% penicillin (10.000 U/ml) / streptomycin (10 mg/ml) solution (Invitrogen) in a humidified atmosphere at 37 °C with 5% CO 2 .
Material and methods

Materials
Patient samples
Frozen samples were obtained from patients undergoing routine surgery at the Department of Obstetrics and Gynecology, Medical University of Vienna. Informed consent was obtained from all patients, and permission for the study was obtained from the ethical committee of the institution. Pathological inspection revealed that all tumors were serous epithelial carcinomas. Patient characteristics, tumor staging and grading [31] are summarized in Table 1 . Total RNA from healthy ovary tissue was obtained from Stratagene (La Jolla, CA).
TaqMan ® real-time RT-PCR
Total RNA from OVCAR-3 and SK-OV-3 cancer cells and human ovarian cancer tissues was isolated using the RNeasy ® Mini kit (Qiagen, Hilden, Germany), and the RNA was treated with RNase-free DNase (Qiagen) to remove genomic DNA. The concentration, purity and integrity of the RNA samples were determined using a Nanodrop ND-1000
(Kisker-Biotech, Steinfurt, Germany) and agarose gel electrophoresis. 1 µg of total RNA was reverse-transcribed in 20-µl reactions using the High-Capacity cDNA RT kit (Applied Biosystems, Foster City, CA) with the provided random hexamer primers and RNase inhibitor (Applied Biosystems) according to the manufacturer's instructions.
TaqMan ® Gene Expression Assays (Applied Biosystems) were purchased for all eleven human OATPs and four transporters from the ABC family ( 
Immunohistochemistry
Immunohistochemistry staining experiments were done on 4-µM paraffin sections from ovarian cancer samples. Before application of antibodies, antigen retrieval was performed for 2 minutes in citrate buffer using a microwave oven (R-208, Sharp
Electronics Europe, Vienna, Austria 
Cytotoxicity assay
A
Preparation of OATP cDNA for the expression in X. laevis oocytes
The plasmids containing human full-length cDNA from OATP1B1 (pSPORT1) and OATP1B3 (pSPORT1) were originally cloned from a human liver cDNA library, and OATP2B1 (pCMV6-XL4) was cloned from a human brain cDNA library [33] . OATP1A2
(pDRIVE, IHS1382-8428120), OATP2A1 (pOTB7, EHS1001-6793541) and OATP4C1 NM_173488.3). In OATP3A1, we found a polymorphism for 1083G>C, resulting in the amino acid exchange of Glu294Asp. For OATP5A1, we detected an SNP at 1406C>G, leading to the amino acid exchange of Leu264Val. No polymorphisms were found in OATP6A1.
Linearization, template preparation, and in vitro transcription of OATP cRNA
All plasmid inserts were verified for correct sequence and orientation by sequencing (MWG). For the in vitro synthesis of cRNA, the cDNA clone of OATP4A1 was linearized with BglII, and Mlul was used for the linearization of OATP1B1 and OATP1B3 plasmids.
For OATP3A1, OATP4C1, OATP5A1 and OATP6A1, we used XbaI for linearization.
OATP1C1 was linearized with Acc65I, and OATP2A1 was linearized with DraI. All and OATP2B1 PCR products were gel-purified and used as templates for in vitro transcription. 5'-capped cRNAs were transcribed in vitro using 1 µg of template DNA and either T7 or SP6 mMESSAGE mMACHINE ® kit (Ambion, Austin, TX) according to the manufacturer's instructions. Subsequently, the cRNAs were polyA-tailed using the polyA tailing kit (Ambion) according to the protocol. The polyA cRNA was then purified using the MEGAClear™ kit (Ambion). The concentration, purity and integrity of cRNA samples were determined on a Nanodrop ND-1000 (Kisker-Biotech) and by denaturing gel electrophoresis.
Paclitaxel transport studies in Xenopus laevis oocytes
Preparation of stage V-VI oocytes from X. laevis was performed as previously described [34] . [³H]paclitaxel were manipulated using glassware. For kinetic analysis, the uptake of radiolabeled paclitaxel was measured over a range of concentrations, from 20 to 1180 nM, using 60-min incubations within the linear component of uptake. Uptake was corrected for non-specific influx using water-injected oocytes from the same batch in each experiment. Uptake was stopped by the addition of 3 ml ice-cold uptake buffer, and oocytes were washed three times with buffer before being placed in scintillation vials for dissolution with 10% SDS overnight. Radioactivity was measured in a liquid scintillation counter (LS-6500; Beckman, California, USA).
Western blot analysis of OATP1B1 and 1B3 in X. laevis oocytes
Oocyte protein expression and membrane localization of human OATP1B1 and OATP1B3 were confirmed by western blot using membrane and cytosolic protein fractions from OATP1B1-and OATP1B3-injected oocytes [35] . A total of 10 µg of protein was separated on 10% separating gels, blotted on PVDF membranes and probed using an antibody against OATP1B1/1B3 (#BM5541, Acris) diluted 1:250 in TBS-T (20 mM Tris, 145 mM NaCl, 0.05% Tween 20, pH 7.6) containing 5% milk powder [36] . On control blots, an antibody to α-tubulin (Sigma, T-5168) was diluted 1:8000 in TBS-T containing 5% milk powder. The HRP-conjugated secondary antibody (#315-036-003, Jackson ImmunoResearch, Suffolk, UK) was used at a dilution of 1:10000 in TBS-T.
Transport experiments in OVCAR-3 and SK-OV-3 cells
Cells that were 80-90% confluent were washed three times and incubated for 15 min 
Data analysis
For kinetic analysis, data were fitted to the Michaelis-Menten (hyperbolic) model. Kinetic parameters were estimated using Prism 5 software (GraphPad) for Michaelis-Menten kinetics:
where V is the rate of reaction, V max is the maximum velocity, K m is the Michaelis constant, and S is the substrate concentration. Unless otherwise indicated, values are expressed as the mean ± SD of at least 12 individual oocytes per data point. Statistical differences from control values were evaluated using a Student's t-test, and the level of statistical significance was set at P < 0.05.
Results
Expression of OATPs in human ovarian cancer specimens
To assess the role of OATP transporters for paclitaxel uptake, we investigated the mRNA expression of all 11 human OATPs in a series of ovarian cancer tissue samples using TaqMan ® real-time RT-PCR. Total RNA from normal ovary served as control. As shown in Table 3 , mRNA of all 11 OATPs was observed in specimens of ten ovarian cancer patients at quite different levels (from 0.02-fold to 103-fold compared to the endogenous control gene HPRT1), whereas in normal ovaries, mRNA expression was confined to five OATP family members (OATP2A1, OATP2B1, OATP3A1, OATP4A1 and OATP5A1). In normal ovary tissue, OATP1B1 and OATP1B3 mRNA expression was below the detection limit, whereas OATP1B3 was clearly detected in 5/10 ovarian cancer specimens. Interestingly, three of the five OATP1B3-expressing samples also expressed OATP1B1. These data were confirmed by immunohistochemistry, demonstrating that protein levels of OATP1B1 and 1B3 correlate with mRNA expression in cancerous tissue (a representative tumor sample is shown in Fig. 1A ). In line with real-time RT-PCR, no staining for these proteins was observed in noncancerous tissue (Fig. 1B) .
OATP mRNA expression in ovarian cancer cells
We further investigated the mRNA expression profile of all human OATPs in the human ovarian carcinoma cell lines OVCAR-3 and SK-OV-3. Interestingly, expression of the liver-specific OATP1B3 mRNA was up to 204-fold higher in SK-OV-3 cells compared to OVCAR-3 cells (Table 4) . Even more pronounced was the difference in OATP1B1 expression, as this transporter was only found in SK-OV-3 cells. A different expression pattern was also observed for OATP2B1, which was 71-fold higher in SK-OV-3 cells, and for OATP5A1, which was 85-fold higher in the OVCAR-3 cell line. mRNA expression of OATP1A2, OATP2A1, OATP3A1, OATP4A1 and OATP4C1 was detected in OVCAR-3 and SK-OV-3, although the observed distribution was more balanced.
Expression levels of OAT2 (previously identified as a potential paclitaxel transporter) [26] , OATP1C1 and OATP6A1 were below the detection limit in both cell lines.
Expression of paclitaxel efflux transporters in ovarian cancer cell lines
Despite differing expression of OATP1B1 and OATP1B3, OVCAR-3 and SK-OV-3 cells displayed similar paclitaxel cytotoxicity. As overexpression of OATP increased the cytotoxicity of paclitaxel, the comparable sensitivity of naive OVCAR-3 cells to paclitaxel could be influenced by the different expression levels of efflux pumps. Therefore, we further investigated the expression of four major paclitaxel efflux transporters in these two cell lines. We indeed observed up to 18-fold higher mRNA expression levels for MRP2 and MRP3 in SK-OV-3 cells (Table 5) , suggesting a higher efflux of paclitaxel out of the cytoplasm into the cellular supernatant. MDR1 and MRP7 were similar in distribution between the two cell lines.
Paclitaxel transport studies in X. laevis oocytes
To investigate whether OATPs other than OATP1B3 contribute to paclitaxel uptake into (Fig. 4A) . Transport of paclitaxel into the SK-OV-3 cell line was far more pronounced, showing an uptake rate of 1660 ± 126 pmol/mg protein/min at a concentration of 10 µM. Because of the limited solubility of this drug in serum-containing cell culture medium, saturation kinetics could not be observed (Fig. 4B ).
Paclitaxel cytotoxicity in OATP1B1-and OATP1B3-transfected SK-OV-3 cells
To investigate whether increased expression of either OATP1B1 or OATP1B3 could have an impact on paclitaxel cytotoxicity we tested the efficacy of paclitaxel in OATP1B1-and OATP1B3-transfected SK-OV-3 cells. As shown in Fig. 5 , the IC 50 was decreased to 2.8 ± 1.38 nM for paclitaxel in OATP1B1 cells and to 3.4 ± 1.27 nM in OATP1B3 cells (compared to 4.9 ± 1.35 nM in cells transfected with the empty vector).
Discussion and conclusion
In the present study, we elucidated the transcriptional expression for human OATPs in malignant and control ovarian tissue samples and in estrogen-responsive OVCAR-3
and estrogen-independent SK-OV-3 ovarian cancer cell lines, By investigation of all 11 known OATPs by TaqMan ® real-time RT-PCR, we found that OATP1B1, OATP1B3 and OATP2B1 were highly expressed in SK-OV-3 cells, whereas OATP1A2, OATP4C1 and OATP5A1 were primarily present in OVCAR-3 cells.
The two transporters OATP1C1 and OATP6A1 were not detectable in either cell line. It should be noted that expression of OAT2, which was previously shown to mediate the uptake of paclitaxel in X. laevis oocytes, was below the detection limit in both cell lines.
Our data are consistent with the previous work of Okabe and coworkers, who showed similar differences of OATP expression in OVCAR-3 and SK-OV-3 cells [24] . However, contrary to their study, we were unable to confirm expression of OATP6A1 in the OVCAR-3 cell line.
To date, the only OATP that has been characterized as a high-affinity paclitaxel transporter [25] is OATP1B3. Uptake of paclitaxel was significantly reduced in the OATP1B3-expressing cell line HepG2 but not in OATP1B3-deficient PR-HepG2 cells by the OATP1B3 substrate and inhibitor bromosulfophtalein [37] . By systematically investigating the transport properties of paclitaxel for all 11 OATPs using the X. laevis oocytes expression system, we were able to identify OATP1B1 as an additional uptake protein for paclitaxel. Indirect involvement of OATP1B1 in taxane transport was reported by Gui and coworkers who showed inhibition of the OATP1B1 substrate estradiol-17β-glucuronide by paclitaxel in stable transfected CHO cells [38] . An involvement of OATP1B1 in hepatic clearance of paclitaxel may explain the finding of a pharmacogenetic investigation of variants of the SLCO1B3 gene; Smith and coworkers found that differences in paclitaxel pharmacokinetics did not correlate with different OATP1B3 variants [39] . Nevertheless, one variant has recently been shown to influence the pharmacokinetics of mycophenolate [40] .
Several ABC transporters have been shown to successfully expel paclitaxel from the cells. Importantly, it has been demonstrated that MDR1 and MRP2, as well as MRP3 and MRP7, mediate paclitaxel transport [7] [8] [9] [10] . However, exposing SK-OV-3 cells transiently overexpressing OATP1B1 and OATP1B3 to paclitaxel decreased their IC 50 , indicating that the sensitivity of the ovarian cancer cells to paclitaxel can be modulated by OATP1B1/1B3 expression levels. Using TaqMan ® real-time RT-PCR, we identified higher expression levels of MRP2 and MRP3 in SK-OV-3 cells, whereas differences of MDR1 and MRP7 mRNA expression were moderate. MRP2 and MRP3 may therefore facilitate increased efflux of paclitaxel in SK-OV-3 cells.
Our data suggest that OATP1B1 might be an even more important determinant of paclitaxel uptake in ovarian cancer cells than OATP1B3, based on its lower K m value in X. laevis oocytes (0.6 µm vs. 1.6 µM). This K m is in the range of the mean plasma concentration in patients (0.85 ± 0.21 µM) after 24 h of infusion [41] . Our conclusion that paclitaxel could be a better substrate for OATP1B1than OATP1B3 is supported by very recent experiments of Gui and coworkers as they found that paclitaxel (2.5 µM) inhibited the uptake of the OATP1B1/1B3 substrate fluorescein-methotrexate by 93% in OATB1B1-but only by 53% in OATP1B3-expressing CHO cells [42] . Differences in estrogen-responsive and estrogen-independent ovarian cancer cell lines also suggest that alterations in mRNA expression levels may also be observed in tumor tissue samples from patients. It is known that the activity and the expression of transport proteins may vary greatly between individuals, as a function of genetic, environmental, and physiological factors. Indeed, we also demonstrated great differences in the expression of all 11 OATPs in 10 ovarian cancer specimens and one control tissue sample (Table 3) . Among these polypeptides, expression of OATP1A2, OATP1B1, OATP1B3, OATP1C1, and OATP6A1 was found exclusively in the tumor samples but not in the control one.
OATP1B1-and OATP1B3-mediated paclitaxel transport may be of clinical importance, as our data show for the first time that both transporters are also expressed in ovarian cancer specimens but not in control tissue. This expression is remarkable, since OATP1B1 and OATP1B3 are proposed to be expressed under normal conditions in liver only [14] . As the expression of both OATPs are positively regulated by the transcription factor HNF1α [43] , any upregulation of HNF1α may subsequently increase OATP1B1
and 1B3 levels. Indeed, Tomassetti and coworker demonstrated that vHNF1 (the variant isoform of the hepatocyte nuclear factor 1) is highly expressed in cancer tissue but not in normal ovarian epithelium [44] .
OATP1B1 and OATP1B3 share a wide, overlapping substrate spectrum that includes HMG-CoA reductase inhibitors such as fluvastatin and pitavastatin, the antibiotic rifampicin and the endothelin receptor antagonist BQ123 [45] . The hepatic uptake rate of both transporters might be reduced by drug competition, resulting in increased blood levels. Therefore, inter-individual expression levels of OATP1B1 and OATP1B3 in the basolateral membrane of hepatocytes might be responsible for differences in the occurrence of toxic side effects such as neutropenia, neuropathy and cardiac effects during paclitaxel therapy. Such drug-drug interactions have been reported for the OATP1B1 and OATP1B3 substrates pravastatine and bosentan [46, 47] when concomitantly administered with clarithromycin and cyclosporine or rifampicin, respectively.
In conclusion, we found that OATP1B1 and OATP1B3 are high affinity and active paclitaxel transporters in transfected X. laevis oocytes; this role may also apply for the uptake of this compound into human liver and ovarian cancer cells.
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